Protalix BioTherapeutics, Inc.
PLX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $53,399 | $65,494 | $47,638 | $38,350 |
| % Growth | -18.5% | 37.5% | 24.2% | – |
| Cost of Goods Sold | $24,319 | $22,982 | $19,592 | $16,349 |
| Gross Profit | $29,080 | $42,512 | $28,046 | $22,001 |
| % Margin | 54.5% | 64.9% | 58.9% | 57.4% |
| R&D Expenses | $12,970 | $17,093 | $29,349 | $29,734 |
| G&A Expenses | $0 | $0 | -$13,581 | -$4,020 |
| SG&A Expenses | $12,193 | $14,959 | $11,711 | $12,729 |
| Sales & Mktg Exp. | $0 | $0 | $25,292 | $16,749 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25,163 | $32,052 | $41,060 | $42,463 |
| Operating Income | $3,917 | $10,460 | -$13,014 | -$20,462 |
| % Margin | 7.3% | 16% | -27.3% | -53.4% |
| Other Income/Exp. Net | $237 | -$1,894 | -$1,383 | -$7,120 |
| Pre-Tax Income | $4,154 | $8,566 | -$14,397 | -$27,582 |
| Tax Expense | $1,222 | $254 | $530 | $0 |
| Net Income | $2,932 | $8,312 | -$14,927 | -$27,582 |
| % Margin | 5.5% | 12.7% | -31.3% | -71.9% |
| EPS | 0.04 | 0.12 | -0.31 | -0.62 |
| % Growth | -66.3% | 138.7% | 50% | – |
| EPS Diluted | 0.037 | 0.1 | -0.31 | -0.62 |
| Weighted Avg Shares Out | 72,531 | 67,513 | 48,472 | 44,140 |
| Weighted Avg Shares Out Dil | 81,057 | 82,424 | 48,472 | 44,140 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,299 | $1,286 | $1,146 | $401 |
| Interest Expense | $1,062 | $3,180 | $2,529 | $7,521 |
| Depreciation & Amortization | $1,304 | $1,191 | $1,086 | $1,118 |
| EBITDA | $6,520 | $12,937 | -$10,782 | -$18,943 |
| % Margin | 12.2% | 19.8% | -22.6% | -49.4% |